The Week

Abbott Laboratories (ABT) fell 5.89% this week to close at $101.95, while the S&P 500 lost 0.8%, leaving Abbott roughly 5.09 percentage points behind the benchmark. The four-session week was a steady grind lower: shares opened Tuesday at $108.36 against a weekly high of $108.39, then drifted down every day to an intraweek low of $101.49 on Friday before settling near the bottom. Weekly amplitude was 6.37% on 34.1m shares traded, with average daily volume of 8.5m sitting about 14% below the 60-day median, so the move came on light turnover.

Key Events

The headline company development was FDA approval for Abbott’s TactiFlex Duo ablation catheter to treat patients with abnormal heart rhythms. On the money side, Amundi and IFP Advisors both added to their positions this week. The rest of the news flow was largely session-level: for three consecutive days Abbott was flagged as underperforming rivals. With no earnings or large M&A in the week, the pullback looked more tied to medical-device sector sentiment and the broader risk-off tone than to company-specific news.

Analyst Ratings

As of this week 28 analysts cover Abbott: 18 rate it buy, 4 overweight, 5 hold, and 1 no opinion, with no sell or underweight ratings. The consensus recommendation is buy, and the consensus target price of $120.26 sits about 17.96% above the latest close of $101.95. Targets range from $103 to $135, so dispersion is not trivial. Abbott ranks 7th among 142 rated names in the medical-device industry.

The Week Ahead

The macro calendar dominates next week. Tuesday brings the New York Fed manufacturing index, with a prior reading of 20.6 and a forecast of 14.75. Wednesday is dense: retail sales ex-autos, total retail sales, retail control, import prices, the NAHB housing market index, and EIA weekly crude inventories all land. Abbott itself has no earnings scheduled, so the medical-device group may keep taking its cue from macro risk appetite.

In Short

Abbott drifted lower on light volume this week, yet the sell-side did not waver. Of 28 covering analysts, 22 rate it buy or overweight, and the consensus target price is roughly 18% above spot, which sits in tension with the week’s price action. In the latest session large-lot money was a net buyer while smaller flows were net sellers. The question now is whether macro data stabilise sentiment and whether the low-volume slide runs out of momentum near the 60-day moving average.

This article is generated by LongbridgeAI from market data, for information only and not investment advice.